AbbVie has begun construction on a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois, marking a major step in expanding its U.S. manufacturing capabilities. The move is part of AbbVie’s broader plan to invest over $10 billion in the next decade to develop new manufacturing plants across the country.
Azita Saleki-Gerhardt, AbbVie’s executive vice president and chief operations officer, highlighted the significance of the project in accelerating biopharmaceutical innovation and strengthening domestic production. The new facility will enhance AbbVie’s chemical synthesis capacity and shift API production for select medicines from Europe and Asia to the U.S., supporting treatments in neuroscience, immunology, and oncology.
AbbVie employs 28,000 people nationwide, with a strong presence in all 50 states and Puerto Rico. The $195 million investment in North Chicago will create jobs and expand the company’s manufacturing footprint, which currently supports more than 6,000 workers across 11 U.S. sites. This expansion underscores AbbVie’s ongoing commitment to Illinois, where it is headquartered and employs over 11,000 people focused on developing innovative medicines for patients globally.